profit from every $100 of sales.
$0$100
Sangamo Therapeutics
We have no price for Sangamo Therapeutics since 1 July 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$0.07+0.00% today
-89.0% since Oct 13, 25
1-year low $0.051-year high $0.69
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Sangamo Therapeutics sold, what it kept, and what it did with the cash.
Sales went from $111 million in 2022 to $39.6 million in 2025, with -$123 million of profit last year.
SalesProfit
Sangamo Therapeutics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Sangamo Therapeutics | No profit yet | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Sangamo Therapeutics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 111 | 176 | 58 | 40 | |
| – | – | – | – | |
| -201 | -119 | -98 | -108 | |
| -181 | -97 | -89 | -100 | |
| -192 | -258 | -98 | -123 | |
| -1.25 | -1.48 | -0.49 | -0.44 | |
| – | – | – | – | |
| -180.8% | -67.5% | -170.3% | -273.1% | |
| -172.8% | -146.3% | -169.4% | -310.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 563 | 165 | 102 | 60 |
| Cash | 100 | 45 | 42 | 21 |
| Total debt | 43 | 38 | 31 | 27 |
| Total liabilities | 268 | 82 | 79 | 74 |
| 295 | 83 | 23 | -14 | |
| 154 | 174 | 202 | 280 | |
| -47.0% | -77.7% | -145.8% | -681.1% | |
| -65.2% | -311.1% | -430.1% | 861.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -224 | -225 | -67 | -97 | |
| 20 | 21 | 0 | 0 | |
| -244 | -246 | -67 | -97 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 32 | 27 | 12 | 9 |
Valuation
- –
- –
- –
- –
- 0.8×
- –
- –
- -317.4%
- -401.0%
- –
Profitability
- –
- -273.1%
- -310.8%
- –
- –
- –
- –
- –
- –
- –
Growth
- −29.2%
- –
- –
- –
- –
Financial health
- –
- –
- –
- –
- –
- –
- –
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 908
What analysts expect
- Average price target
- $7.25
- Range
- $2.00 – $19.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 14, 2026 | -0.08 | 0.01 | −1,700.0% |
| Mar 30, 2026 | -0.11 | 0.01 | −1,318.2% |
| Nov 6, 2025 | -0.11 | -0.03 | −266.7% |
| Aug 7, 2025 | -0.08 | -0.07 | −14.3% |
| May 12, 2025 | -0.14 | -0.11 | −27.3% |
| Mar 17, 2025 | -0.11 | -0.09 | −22.2% |
| Nov 12, 2024 | 0.04 | 0.01 | +237.8% |
| Aug 6, 2024 | -0.17 | -0.16 | −6.3% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/6Passes 0 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
47No pass
Benjamin Graham
9No pass
Philip Fisher
50No pass
Peter Lynch
2No pass
Joel Greenblatt
–Not enough data
Charlie Munger
31No pass
Terry Smith
27No pass
Questions about Sangamo Therapeutics
Is Sangamo Therapeutics a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Sangamo Therapeutics AI analysis
What does Sangamo Therapeutics do?
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. It is in Biotechnology.
Does Sangamo Therapeutics pay a dividend?
No. Sangamo Therapeutics does not pay a dividend at the moment.
Who are Sangamo Therapeutics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with Sangamo Therapeutics's.
Prices: daily closes to Jul 1, 2026. Fundamentals: company reports via invest-like data.